Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, with significant net income and EPS growth, and a robust cash position. The Q&A session indicates positive global market trends and strategic pipeline developments. Despite some management ambiguity, the overall sentiment is optimistic, supported by strong ex-U.S. growth, positive KB803 launch expectations, and successful at-home administration of VYJUVEK. These factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Net Revenue from VYJUVEK $116.4 million for Q1 2026, a 9% sequential growth from Q4 2025 and a 32% increase compared to Q1 2025. Growth attributed to global sales, including launches in Europe and Japan.
Cumulative Net Revenue from VYJUVEK since launch Over $846 million. Reflects strong global adoption and sales performance.
Gross Margin 95% for Q1 2026, up from 94% in Q1 2025. Improvement due to manufacturing process efficiencies for the U.S. market.
Net Revenue from Europe and Japan $28.9 million for Q1 2026. Demonstrates meaningful contribution from international markets.
Net Revenue from the United States $87.5 million for Q1 2026. Impacted by insurance switchovers and start-stop treatment cadence.
Cost of Goods Sold $6.3 million for Q1 2026, compared to $5 million in Q1 2025. Increase due to higher production costs.
R&D Expenses $15.3 million for Q1 2026, up from $14.3 million in Q1 2025. Increase driven by payroll, materials, and production support costs for multiple product candidates.
G&A Expenses $41 million for Q1 2026, up from $32.6 million in Q1 2025. Increase due to higher headcount, compensation, legal, consulting, and global launch support costs.
Net Income $55.9 million for Q1 2026, compared to $35.7 million in Q1 2025. Growth attributed to increased revenue and operational efficiencies.
Earnings Per Share (EPS) $1.91 per basic share and $1.83 per diluted share for Q1 2026, compared to $1.24 per basic share and $1.20 per diluted share in Q1 2025. Reflects improved profitability.
Cash and Investments Exceeding $1 billion as of Q1 2026. Indicates strong financial position to support pipeline and global commercial efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYJUVEK Revenue Growth: Net revenue of $116.4 million in Q1 2026, cumulative revenue since launch exceeds $846 million. 9% sequential growth compared to Q4 2025. Gross margin at 95%.
Pipeline Advancements: FDA granted platform technology designations to KB407 for CF, KB111 for Hailey-Hailey, and KB801 for NK. These designations streamline development and reduce risks.
Clinical Trials: Two registrational study readouts expected in 2026 for KB803 and KB801. Additional studies for KB407, KB111, KB408, and KB707 are progressing.
International Expansion: VYJUVEK launched in Europe and Japan, contributing $28.9 million in net revenue. Plans to expand to Italy and Spain in the second half of 2026.
U.S. Market Performance: Net revenue of $87.5 million in Q1 2026. Over 695 reimbursement approvals and 570 unique prescribers since launch.
Financial Strength: Net income of $55.9 million in Q1 2026, with EPS of $1.91 per basic share. Cash and investments exceed $1 billion.
Operational Efficiency: Gross margin improved to 95% due to manufacturing process improvements. R&D and SG&A expenses projected at $175-$195 million for 2026.
Global Commercial Strategy: Focus on disciplined execution, geographic diversification, and building trust with physicians and patients to ensure long-term growth.
Patient-Centric Approach: Initiatives to enhance patient support and education, including flexibility in VYJUVEK administration and long-term treatment integration.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Insurance Changes Impacting Revenue: Higher-than-usual level of insurance changes in Q1 2026 impacted revenue growth, a challenge faced by many biotech companies.
Pricing Negotiations in Europe: Ongoing pricing negotiations in Germany and France, with decisions expected in 2026 and 2027 respectively, could delay broader access and reimbursement stability.
Regulatory and Reimbursement Challenges: Discussions with reimbursement authorities in Italy and Spain are ongoing, with potential launches dependent on successful negotiations.
Start-Stop Treatment Paradigm: The start-stop treatment cadence in the U.S. is impacting revenue patterns as patients transition to maintenance regimens.
Operational Costs: Increased R&D and G&A expenses due to higher headcount, compensation, legal, consulting, and global launch support costs.
Country-Specific Launch Nuances: Challenges include prescription renewal frequency in Japan, mandatory first physician visits, and varying regulatory requirements across countries.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Registrational Study Readouts: Two registrational study readouts are expected later this year (2026) and two more in 2027. These include KB803 for corneal abrasions in DEB patients and KB801 for neurotrophic keratitis.
Pipeline Development: The company plans to initiate two open-label studies for KB407 (Cystic Fibrosis) and KB111 (Hailey-Hailey Disease) with data expected later this year. Registrational studies for these programs are expected to commence in 2027.
Global Expansion of VYJUVEK: The company is working to deepen penetration in current launch markets, secure positive access and reimbursement outcomes, and expand into additional European markets such as Italy and Spain in the second half of 2026. Pricing decisions in Germany and France are expected in the second half of 2026 and 2027, respectively.
Revenue Growth: The company anticipates significant growth opportunities for VYJUVEK in the coming years by driving new patient starts and maximizing convenience for patients already on therapy.
Financial Guidance: Non-GAAP R&D and SG&A expenses for the full year of 2026 are expected to be approximately $175 million to $195 million.
Cystic Fibrosis Program (KB407): The company expects to complete enrollment in an open-label study for KB407 later this quarter and report data by the end of the year. A registrational study is expected to commence in the first half of 2027.
Hailey-Hailey Disease Program (KB111): The company plans to initiate an open-label safety study for KB111 later this month and submit a registrational study design to the FDA in the second half of 2026. The registrational study is expected to start in 2027.
Other Pipeline Updates: Data updates for KB408 (AATD lung disease) and KB707 (non-small cell lung cancer) are expected later this year, with KB707 data to be presented at ASCO next month.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the growth trajectory in the U.S. for the rest of 2026 and the strong trend in ex-U.S. markets like Europe and Japan?
A:The U.S. market is growing well with a 60% market share and steady progress towards identified patient numbers. However, quarterly growth is unpredictable due to start-stop dynamics. Ex-U.S. markets like Europe and Japan show strong trends, and the overall global trajectory for 2026 looks positive.
Q:What will be the endpoint for the 24-week CF data readout, and what will be the go/no-go decision before starting the pivotal trial?
A:The endpoint is to establish safety in repeat dose administration. The company is working with the FDA and CFF Foundation on an innovative trial design and expects to start the registrational trial early next year after gaining concurrence on the design.
Q:How should we think about the potential launch trajectory of KB803 compared to VYJUVEK?
A:The launch trajectory for KB803 is expected to be positive due to lessons learned from VYJUVEK, including supply chain mechanisms and patient identification. The drug could address 50% of the RDEB population and 10-15% of the dominant population, with potential for broader use.
Q:Why was the Hailey-Hailey registration pushed out to 2027, and what data should we expect later this year?
A:The delay is due to the need to validate a patient-reported outcome scale and conduct a small Phase I study to collect safety, dosing regimen, and scale validation data. The registrational trial is expected to start early next year and enroll rapidly due to a decentralized study design.
Q:What are the key differences in the ex-U.S. launch of VYJUVEK compared to the U.S.?
A:Physician education has been easier in Europe and Japan due to awareness of VYJUVEK's benefits. Negotiations in Europe involve political factors and rare disease budgets, with outcomes in Germany and Italy expected to influence pricing in other countries.
Q:Are there insurance frictions around the stop-start drug holidays for VYJUVEK?
A:There have been no issues with access, reimbursement, or reauthorization for VYJUVEK. Start and stop decisions are made by patients and physicians, and reauthorization has been smooth.
Q:What are the prescribed definitions for CF patients who do not tolerate or benefit from modulators, and why is repeat dose data needed?
A:There are no specific markers like sweat chloride for these patients. Repeat dose data is needed because previous studies only involved single-dose administration. The new study will evaluate weekly repeat doses over six months, focusing on safety and exploratory functional data.
Q:What is the pricing model for VYJUVEK in Spain and Italy, and how many patients are estimated in these territories?
A:Spain and Italy are expected to have definitive reimbursement models, unlike the accrual models in Germany and France. The prevalence of patients in Spain is expected to be similar to other European countries.
Q:What is the impact of at-home administration of VYJUVEK in the U.S.?
A:At-home administration has been well-received, allowing patients more flexibility and comfort. It has encouraged some patients to initiate therapy and others to transition from nurse-administered to self-administration, supporting better integration into daily routines.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical data or clear predictions for the quarterly growth trajectory in the U.S. and ex-U.S. markets, as well as the exact pricing outcomes in European countries like Spain and Italy. Additionally, they did not provide detailed functional data expectations for the CF repeat dose study or specific baseline symptom data for the KB803 trial.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFF
Conference
Europe Japan
HALITE
HHD
Head Commercial
KB program
KB week
RD
Spain
Suma
United States
VP Head
VYJUVEK focus
access reimbursement
analysis plan
autonomy
design analysis
designation
development plan
dose KB
ease
enrollment study
insurance switchovers
interaction
label update
launch Europe
launch market
life
outcome negotiation
patient start
region
study readout
support VYJUVEK
treatment option
week patient
year
KRYS Transcript
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call highlights strong financial performance, with significant net income and EPS growth, and a robust cash position. The Q&A session indicates positive global market trends and strategic pipeline developments. Despite some management ambiguity, the overall sentiment is optimistic, supported by strong ex-U.S. growth, positive KB803 launch expectations, and successful at-home administration of VYJUVEK. These factors suggest a positive stock price movement over the next two weeks.
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong financial performance, global market expansion, and strategic pipeline developments. Despite some uncertainties in pricing and compliance, the overall sentiment is positive due to strong revenue growth, operational efficiency, and a well-positioned cash reserve. The Q&A section reinforces this with management's confidence in global demand and strategic focus on pipeline investment. The absence of immediate stock buybacks is offset by the promising outlook on market expansion and product adoption, suggesting a positive stock price movement.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
KRYS Slides
KRYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
